Abstract

Several phase II trials have reported that, compared with standard-dose fibrinolytic therapy, intravenous glycoprotein (GP) IIb/IIIa inhibition

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call